Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study-Reference-Cited by-同舟云学术

Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study

Published:2020-07 Issue:10245 Volume:396 Page:186-197
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Dimopoulos Meletios,Quach Hang,Mateos Maria-Victoria,Landgren Ola,Leleu Xavier,Siegel David,Weisel Katja,Yang Hui,Klippel Zandra,Zahlten-Kumeli Anita,Usmani Saad Z

Publisher

Elsevier BV

Subject

General Medicine

Reference31 articles.

1. Overall survival of transplant eligible patients with newly diagnosed multiple myeloma: comparative effectiveness analysis of modern induction regimens on outcome;Paquin;Blood Cancer J,2018

2. Improved survival in multiple myeloma and the impact of novel therapies;Kumar;Blood,2008

3. Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial;Dimopoulos;Lancet Oncol,2017

4. How have evolutions in strategies for the treatment of relapsed/refractory multiple myeloma translated into improved outcomes for patients?;Sonneveld;Crit Rev Oncol Hematol,2017

5. Current and new therapeutic strategies for relapsed and refractory multiple myeloma: an update;Nijhof;Drugs,2018

Cited by 324 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cardiac Complications of Multiple Myeloma Treatments;Cardiology in Review;2024-09-10

2. Efficacy of daratumumab on multiple myeloma patients with renal insufficiency: a systematic review and meta-analysis;Hematology;2024-09-09

3. Updates on Therapeutic Strategies in the Treatment of Relapsed/Refractory Multiple Myeloma;Cancers;2024-08-23

4. The Role of Monoclonal Antibodies in the Treatment of Myeloma Kidney Disease;Pharmaceuticals;2024-08-05

5. Serum Free Light Chain Kinetics Is Predictive of Renal Response in Myeloma Patients With Renal Impairment—An ALLG Trial of Carfilzomib-Dexamethasone Therapy in Frontline and Relapse;Clinical Lymphoma Myeloma and Leukemia;2024-08